Registration 333-298364
F-1 · 2026-08-17 · 0001213900-26-090325
Terms from the governing filing for this registration; not a claim that the offering is open today.
Security
Optimi Health Corp. Common Shares · OPTH
OPTHNASDAQCommon stockCurrentCIK 2027329Updated Oct 27, 2026
OPTH price & chart
Loading TradingView…
NASDAQ:OPTH on TradingView ↗About the company
We are a Canadian Good Manufacturing Practices (“GMP”) compliant, pharmaceutical drug manufacturer licensed by Health Canada for the handling of controlled substances and GMP production. We specialize in controlled substances with our products being 3,4-Methylenedioxymethamphetamine hydrochloride (“MDMA”) and psilocybin derived from botanical sources. With a vertically integrated approach, we own two approximately 10,000-square-foot production facilities on leased land in Princeton, British Columbia and operate under a Drug Establishment Licence (“DEL”) awarded by Health Canada. Our DEL certifies that our facilities and quality management systems comply with GMP for the formulation of designated drug products and the manufacture of certain active pharmaceutical ingredients (“API”) from plant sources. Additionally, we hold a Dealer’s Licence (“DL”) under Canada’s Narcotic Control Regulations, allowing us to possess, produce, assemble, sell, and deliver psilocybin and other psychedelic substances within the regulated framework set forth by Health Canada. The DL allows us to possess up to 20kg of psilocybin and 200g of psilocin (equivalent to approximately 2,000kg of dried full-body p…
In the news
No coverage from other publishers is available.
Recent filings
6-K filing
6-K filing
6-K filing
SCHEDULE 13G/A - filed by YA II PN, Ltd. regarding Optimi Health Corp.
6-K filing
Show 5 more recent filings
Offerings
Registration 333-298364
Registration 333-290086
- Gross proceeds
- 15000000.0
- Net proceeds
- 13875000.0
- Deal price
- 6.25
- Shares
- 2400000
- Offering price
- $6.25
- Ticker
- OPTI
Underwriters: UNDERWRITER, Joseph Gunnar & Co., LLC
Filing attachments
ea030225801ex99-1.htm · 6-K · 2026-08-14
Exhibit 99.1 Optimi Health Establishes Discretionary Equity Facility VANCOUVER, British Columbia, August 14, 2026 (GLOBE NEWSWIRE) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it has entered into a common shares purchase agreement (the “Purchase Agreement”) with Seven Knots, LLC (“Seven Knots”), establishing an equity line of credit (the “ELOC”…
Read attachment ↗ea030225801ex99-2.htm · 6-K · 2026-08-14
Exhibit 99.2 COMMON Shares PURCHASE AGREEMENT This COMMON SHARES PURCHASE AGREEMENT is made and entered into as of August 13, 2026 (this “Agreement”), by and among Seven Knots, LLC, a Montana limited liability company (the “Investor”), and Optimi Health Corp., a corporation incorporated under the Business Corporation Act (British Columbia) (the “Company”). RECiTALS WHEREAS, the parties desire that, upon the terms and subject to the conditions and limitations set forth herein, the Company may…
Read attachment ↗ea029942101ex99-1.htm · 6-K · 2026-07-28
Exhibit 99.1 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING AND MANAGEMENT INFORMATION CIRCULAR with respect to the Annual General and Special Meeting of Shareholders to be held on Monday, August 13, 2026 Dated as of July 6, 2026 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT the annual general and special meeting (the “Meeting”) of the shareholders of Optimi Health Corp. (“Optimi” or the “Corporation”) will be held via hybrid, in-person at Norton…
Read attachment ↗ea029942101ex99-2.htm · 6-K · 2026-07-28
Exhibit 99.2 Optimi Health Corp. Security Class: Common Shares FORM OF PROXY Annual General & Special Meeting of the Shareholders of Optimi Health Corp. (the "Company") to be held on Thursday, August 13, 2026 (the "Meeting") This Form of Proxy is solicited by and on behalf of the management of the Company Notes to proxy Every holder has the right to appoint some other person or company of their choice, who need not be a holder, to attend and act on their behalf at the Meeting or any adjournment…
Read attachment ↗d145470dex991.htm · 6-K · 2026-06-29
Exhibit 99.1 Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025. VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “Company” or “Optimi”), a commercial-stag…
Read attachment ↗d157521dex991.htm · 6-K · 2026-06-16
Exhibit 99.1 Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi’s psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country’s Authorized Prescriber Scheme VANCOUVER, British Co…
Read attachment ↗